New drug MT-2990 tested in tiny early trial for rare vasculitis

NCT ID NCT06196905

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Dec 16, 2025 · Last updated May 14, 2026 · Updated 24 times

Summary

This early study tested the drug MT-2990 in 5 adults with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to explore how well the drug works, its safety, and how it acts in the body. Because this was a very small, exploratory study, there was no single main measure of success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Hiroshima University Hospital

Hiroshima, Hiroshima, 734-8551, Japan
Juntendo University Hospital

Bunkyo-ku, Tokyo, 113-8431, Japan
Kagawa University Hospital

Kita-gun, Kagawa-ken, 761-0793, Japan
Keio University Hospital

Shinjuku-ku, Tokyo, 160-8582, Japan
Kyorin University Hospital

Mitaka-shi, Tokyo, 181-8611, Japan
NHO Tokyo Medical Center

Meguro-ku, Tokyo, 152-8902, Japan
Saitama Medical Center

Kawagoe, Saitama, 350-8550, Japan
Saitama Medical University Hospital

Iruma-gun, Saitama, 350-0495, Japan

Conditions

Explore the condition pages connected to this study.

ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV)